Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

Name: Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors
Published: 2020
License: Public Domain

Chinese PLA General Hospital · 2020

ClinicalTrials.gov · Datasets · License: Public Domain · 2020

Open Source ↗

chemotherapy

solid tumor, unresectable, metastatic, tlr7 agonist, anti-pd-1 antibody, anti-cd47 antibody, chemotherapy, interventional, phase1, phase2

This document is indexed with metadata only — full text is not available in the archive for this record. Open the official source ↗

Study of SHR2150 (TLR7 Agonist) in Combination With Chemotherapy Plus PD-1 or CD47 Antibody in Subjects With Unresectable/ Metastatic Solid Tumors

Related documents